Top ▲

BAFF receptor

Click here for help

Target id: 1886

Nomenclature: BAFF receptor

Abbreviated Name: BAFF-R

Systematic Nomenclature: TNFRSF13C

Family: Tumour necrosis factor (TNF) receptor family

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 184 22q13.2 TNFRSF13C TNF receptor superfamily member 13C
Mouse 1 175 15 E1 Tnfrsf13c tumor necrosis factor receptor superfamily, member 13c
Rat - - Tnfrsf13c TNF receptor superfamily member 13C
Previous and Unofficial Names Click here for help
B cell-activating factor receptor | tumor necrosis factor receptor superfamily, member 13c | BAFFR | Bcmd1 | CD268 | tumor necrosis factor receptor superfamily, member 13C | tumor necrosis factor receptor superfamily member 13C | tumor necrosis factor receptor superfamily
Database Links Click here for help
Alphafold
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Gene
OMIM
Pharos
UniProtKB
Wikipedia
Natural/Endogenous Ligands Click here for help
BAFF {Sp: Human}
Adaptor proteins (Human)
TRAF3

Download all structure-activity data for this target as a CSV file go icon to follow link

Antibodies
Key to terms and symbols Click column headers to sort
Antibody Sp. Action Value Parameter Reference
ianalumab Peptide Immunopharmacology Ligand Hs Antagonist 10.7 pIC50 1
pIC50 10.7 (IC50 1.9x10-11 M) [1]
Description: Inhibition of BAFFR-BLyS binding by the whole Ig mAb.
Other Binding Ligands
Key to terms and symbols Click column headers to sort
Ligand Sp. Action Value Parameter Reference
BAFF {Sp: Human} Peptide Click here for species-specific activity table Ligand is endogenous in the given species Immunopharmacology Ligand Hs - - -
Immunopharmacology Comments
This is a type III membrane bound receptor for B cell activating factor (BAFF). BAFF enhances B cell survival and hence regulates the peripheral B cell population. It is suggested that overproduction of BAFF may enhance the survival of autoreactive B cells, an effect which may contribute in the pathogenesis of autoimmune diseases. The anti-BAFF receptor monoclonal antibody ianalumab (VAY736; Novartis) has progressed to clinical evaluation in autoimmune conditions and B cell malignancies.
Immuno Process Associations
Immuno Process:  Cytokine production & signalling
Immuno Process:  T cell (activation)
Immuno Process:  B cell (activation)
Immuno Process:  Immune regulation
Immuno Process:  Chemotaxis & migration
Immuno Process:  Cellular signalling
Immuno Disease Associations
Disease Name:  Sjögren's syndrome
Disease Synonyms:  no synonynms
Comment:  Molecular target for SS- see NCT02962895 which is designed to evaluate clinical efficacy of anti-BAFF-R mAb VAY736 in SS patients.
Disease X-refs:  Orphanet: ORPHA378
References: 
Disease Name:  Rheumatoid arthritis
Disease Synonyms:  no synonynms
Comment:  Molecular target for RA- see NCT02675803 which was designed to evaluate clinical efficacy of anti-BAFF-R mAb VAY736 in RA patients.
Disease X-refs:  Disease Ontology: DOID:7148
OMIM: 180300
References: 
Disease Name:  Multiple sclerosis
Disease Synonyms:  no synonynms
Comment:  The anti-BAFF-R mAb VAY736 has completed Phase 2 clinical evaluation in RRMS- see NCT02038049.
Disease X-refs:  Disease Ontology: DOID:2377
OMIM: 126200
Orphanet: ORPHA802
References:  2

References

Show »

1. Heusser C, Neugebauer J, Schaadt E, Urlinger S, Woisetschlaeger M. (2010) Compositions and methods of use for therapeutic antibodies. Patent number: WO2010007082A1. Assignee: Novartis. Priority date: 17/07/2008. Publication date: 21/01/2010.

2. Rahmanzadeh R, Weber MS, Brück W, Navardi S, Sahraian MA. (2018) B cells in multiple sclerosis therapy-A comprehensive review. Acta Neurol Scand, 137 (6): 544-556. [PMID:29512131]

Contributors

Show »

How to cite this page